Hematology Frontier

Malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) is a highly aggressive and fatal disease, with innovative treatment strategies being a major focus and challenge in hematology research. Recently, ELA026—a novel monoclonal antibody targeting signal regulatory proteins (SIRP)-a/b1/g—has shown promising preliminary efficacy in clinical trials for treating mHLH. At the 29th European Hematology Association Annual Meeting (EHA 2024) held from June 13-16, Dr. Swaminathan Iyer from the University of Texas MD Anderson Cancer Center, USA and his team reported that ELA026 not only improved the response rate in treatment-naïve mHLH patients but also significantly enhanced their 2-month survival rate. This finding offers new hope for mHLH treatment. Oncology Frontier-Hematology Frontier invited Dr. Swaminathan Iyer to discuss the mechanism and clinical significance of ELA026 in mHLH treatment.

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was held grandly in Harbin from July 26 to 28. The conference aimed to provide a platform for in-depth learning and extensive exchange among experts and scholars in the field of hematological tumors. On this occasion, "Oncology Frontier - Hematology Frontier" invited Dr. Shuhua Yi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , to discuss topics related to Waldenström macroglobulinemia (WM) in an in-depth academic exchange.

The European Hematology Association (EHA) annual meeting, an international conference in the field of hematology, gathers numerous experts and scholars from around the world to share and deeply discuss innovative ideas and scientific and clinical research advancements in hematology, promoting continuous development in the field. At this year's conference, the research results on spleen tyrosine kinase (SYK) inhibitors received significant attention. Sovleplenib (HMPL-523), the first SYK inhibitor from China (as of publication date) to apply for market approval, showcased its potential in treating hematological diseases at this EHA meeting. Oncology Frontier - Hematology Frontier has invited Dr. Bing Han from Peking Union Medical College Hospital to provide an in-depth interpretation of the research on Sovleplenib in the field of warm autoimmune hemolytic anemia (wAIHA), aiming to provide references for clinical practice.

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was held grandly in Harbin from July 26 to 28. The conference aimed to provide an important platform for in-depth learning and extensive exchange among experts and scholars in the field of hematological tumors. On this occasion, "Oncology Frontier - Hematology Frontier" specially invited Dr. He Huang from The First Affiliated Hospital , Zhejiang University School of Medicine to discuss the frontier topic of cellular immunotherapy.

To further enhance the diagnosis and treatment of leukemia and lymphoma in China, the 8th Hematology Academic Conference, jointly organized by the Chinese Society of Clinical Oncology (CSCO), CSCO Leukemia Expert Committee, and CSCO Lymphoma Expert Committee, and co-hosted by Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. On this occasion, "Oncology Frontier - Hematology Frontier" invited Dr. Erlie Jiang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to discuss the frontier topic of hematopoietic stem cell transplantation (HSCT).

In the sweltering summer, we gather in Ice City. The “8th Annual Hematology Conference” organized by the Chinese Society of Clinical Oncology (CSCO), the CSCO Leukemia Expert Committee, and the CSCO Lymphoma Expert Committee, and hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28, 2024. Renowned experts and scholars from both domestic and international arenas came together to present and discuss research in leukemia, lymphoma, and myeloma, as well as address hot topics in clinical practice. On the first day of the conference, we were honored to interview Dr. Jun Ma, the conference chairman and director of the Harbin Institute of Hematology and Oncology, to share the highlights and core concepts of this year’s event.

Editor's Note: In the scorching summer, experts gathered in the cool city of Harbin for the 8th Hematology Academic Conference, organized by the Chinese Society of Clinical Oncology (CSCO), CSCO…

The annual meeting of the European Hematology Association (EHA) is an international conference in the field of hematology, bringing together numerous experts and scholars from around the world to share and delve into innovative ideas and research progress, promoting continuous development in the field of hematology. This year, the research achievements of spleen tyrosine kinase (SYK) inhibitors attracted significant attention. HMPL-523 (Solepinib), the first SYK inhibitor from China to apply for market approval (*as of the press date), presented multiple research results at the EHA conference. In this issue, "Oncology Frontier - Hematology Frontier" invited Dr. Jing Sun from the Department of Hematology at Nanfang Hospital, Southern Medical University, to provide an in-depth interpretation of the ESLIM-01 study (NCT05029635) on Solepinib in the treatment of primary immune thrombocytopenia (ITP), aiming to offer clinical practice insights.

From July 5th to 7th, the highly anticipated 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China were grandly held in Guangzhou. Based on the actual situation of cancer incidence in China, the conference specially invited authoritative experts in the field of oncology and carefully selected outstanding papers from the 2024 ASCO conference for comprehensive and in-depth interpretation. During the conference, "Oncology Frontier - Hematology Frontier" conducted an exclusive interview with Professor Tiejun Gong from the Harbin Institute of Hematology and Oncology. He shared his profound insights and unique academic perspectives on major studies presented at ASCO this year, the progress of the novel CD3 x CD19 IgG4 bispecific antibody CN201, and the overall status and future prospects of hematologic oncology treatment in China.

TP53 mutations not only profoundly affect the progression trajectory of chronic lymphocytic leukemia (CLL), but are also directly associated with poor prognosis, becoming an important factor that cannot be ignored when assessing disease severity and formulating personalized treatment strategies. At the highly anticipated 29th Annual Congress of the European Hematology Association (EHA 2024), Dr. Consuelo Bertossi from the Department of Internal Medicine III at the University of Ulm in Germany, through an exciting oral presentation, deeply analyzed the "The Landscape of TP53 Mutations and Their Prognostic Impact in Chronic Lymphocytic Leukemia (S101)", providing valuable data and insights for the attendees, which has important guiding value for clinical practice and scientific research exploration. To further discuss this cutting-edge topic, "Oncology Frontier-Hematology Frontier" specially invited Dr. Consuelo Bertossi for an interview on the spot, sharing the impact of TP53 mutations on survival rates, the efficacy of targeted drugs, and future research directions.